Esperion Therapeutics reported $14.15M in Interest Expense on Debt for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Alnylam Pharmaceuticals ALNY:US USD 41.08M 1.52M
Amgen AMGN:US USD 415M 47M
Biogen BIIB:US USD 59.9M 5.9M
Biomarin Pharmaceutical BMRN:US USD 4.68M 820K
Cytokinetics CYTK:US USD 6.8M 4M
Esperion Therapeutics ESPR:US USD 14.15M 113K
Halozyme Therapeutics HALO:US USD 7.51M 4.41M
Intercept Pharmaceuticals ICPT:US USD 5.24M 1.43M
Moderna Inc MRNA:US USD 8M 3M
Nektar Therapeutics NKTR:US USD 6.95M 275K
Pfizer PFE:US USD 313M 2M
Ptc Therapeutics PTCT:US USD 19.48M 2.8M
Regeneron Pharmaceuticals REGN:US USD 17.4M 2.1M
Sarepta Therapeutics SRPT:US USD 14.74M 1.29M
United Therapeutics UTHR:US USD 9.2M 3M